T2 said it's in a strong position to achieve planned portfolio milestones over the next two years, including submitting its next test for FDA clearance next year.
The deal gives Oxford access to Imugen’s Lyme disease tests as well as PCR and immunoassay tests.
A PCR-based look at pathogens and parasites in adult Ixodes ricinus ticks from France identified multiple pathogens in more than 20 percent of adult individuals tested.
RNA sequencing uncovered differentially expressed genes in individuals with Lyme disease at diagnosis, immediately after antibiotic treatment, and six months later.
The reference lab noted unusual melt temperatures in samples processed for Lyme disease, and collaborated with others to find the spirochete in Upper Midwest ticks.
Researchers put together an almost 2-billion-base genome assembly for the deer tick, which can transmit pathogens causing Lyme disease and other conditions.
The partnership will combine Aperiomics' data-analysis and bioinformatics technologies with ResourcePath's next-generation sequencing pathogen-testing services.
The funds will support development of a test for detection of multiple tick-borne diseases that Ceres plans to take through the US Food and Drug Administration.
The companies are co-developing an assay that differentiates previously infected, seropositive Lyme disease patients from newly infected individuals.
The company is currently in discussions with several investor groups and plans to use the funds to expand the reach of the test and prepare for FDA submission.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.